Celcuity

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celcuity and other ETFs, options, and stocks.

About CELC

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. 

CEO
Brian F. Sullivan
CEOBrian F. Sullivan
Employees
87
Employees87
Headquarters
Minneapolis, Minnesota
HeadquartersMinneapolis, Minnesota
Founded
2012
Founded2012
Employees
87
Employees87

CELC Key Statistics

Market cap
3.16B
Market cap3.16B
Price-Earnings ratio
-22.48
Price-Earnings ratio-22.48
Dividend yield
Dividend yield
Average volume
2.01M
Average volume2.01M
High today
$77.50
High today$77.50
Low today
$73.24
Low today$73.24
Open price
$76.00
Open price$76.00
Volume
629.80K
Volume629.80K
52 Week high
$83.00
52 Week high$83.00
52 Week low
$7.58
52 Week low$7.58

CELC News

TipRanks 1d
Celcuity Inc.’s Promising Phase 3 Breast Cancer Study: A Market Game-Changer?

Celcuity Inc. ((CELC)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Un...

TipRanks 1d
Celcuity Inc.’s Promising Study on mCRPC Treatment: Key Insights for Investors

Celcuity Inc. ((CELC)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Un...

Simply Wall St 3d
A Look at Celcuity Valuation Following Phase 3 Breast Cancer and Prostate Cancer Trial Results

Celcuity (NasdaqCM:CELC) delivered a packed update for investors, unveiling fresh results from its VIKTORIA-1 Phase 3 breast cancer trial and new data on its pr...

A Look at Celcuity Valuation Following Phase 3 Breast Cancer and Prostate Cancer Trial Results

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

More CELC News

Simply Wall St 6d
Celcuity Is Up 41.8% After Phase 3 Data Shows Gedatolisib Boosts Survival in Breast Cancer

Celcuity recently announced detailed results from its Phase 3 VIKTORIA-1 trial, showing that gedatolisib significantly improved progression-free survival for pa...

Celcuity Is Up 41.8% After Phase 3 Data Shows Gedatolisib Boosts Survival in Breast Cancer
TipRanks 6d
Celcuity price target raised to $77 from $66 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Celcuity (CELC) to $77 from $66 and keeps a Buy rating on the shares following...

People also own

Based on the portfolios of people who own CELC. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.